国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Zebra Fish (Danio rerio) Diving into Bipolar Disorder

John D Andrew, Abdul A Hathi, Lino Steffy and Manjula Devi

Bipolar disorder is a chronic neurological disorder. It is the 6th major ailment which affect 1% of the world population. Lithium is the only classic drug available because the molecular mechanisms of remain unclear. It is difficult to establish in vitro adequate models for pathological analysis because of the heterogeneity of this disorders. The active principle of herbal preparations like ginseng, ephedra sinica, Brindle berry, clove etc. are able to decrease the symptoms of bipolar disorder. Zebrafish and human share 71% of the same genes and 82% of genes associated with human diseases and rapid development and easy to handle. Due to this fact scientist improved the usage of Zebrafish in preclinical screening, as a prominent model in drug discovery and development for neurological disorders. Different procedures are available to study the stress or depression level. They are highly sensitive to psychotropic drugs and different methods like novel tank test, light and dark box method, cognitive model, social model and net stress model are some of the behavioral models performed on Zebrafish. Our work summarizes the growing utility of Zebrafish in pharmacy research and its benefits to overcome the hurdles in the discovery of drugs for neurological disorders.